Health Care • Biotechnology: Pharmaceutical Preparations
$139.37 ▼ -5.48
(-3.78%)
MKT CAP: $9.37B • VOL: 486.9K
52W L $75 52W H $161
PTGX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $442.8M | $708.0M | $262.2M |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | $0 | $0 | $0 |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$158.1M | $252.8M | -$93.7M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$130.1M | $275.2M | -$79.0M |
| EBITDA (Normalized) | -$156.9M | $253.9M | -$93.7M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $57.7M | $184.2M | -$70.2M |
| Capital Expenditures (CapEx) | $1.6M | $1.4M | $0 |
| Free Cash Flow (FCF) | $56.1M | $182.8M | -$70.2M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -24.5% | 32.8% | -2.4% |
| Cash & Short-Term Equivalents | $128.4M | $97.2M | — |
| Total Debt (Short + Long Term) | $24.1M | $31.2M | $1.20B |
| Total Stockholders' Equity | $614.7M | $675.3M | $2.47B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR PTGX.